INS and type 2 diabetes mellitus: Increasing data have shown that the early use of short-term intensive insulin (STII) therapy can improve β-cell function and induce long-term glycaemic remission in patients with newly diagnosed T2DM without further antidiabetic medication, and thus STII therapy has become a strategy of interest2–5.